Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLX475 and ipilimumab in advanced melanoma
NCT04894994Phase 2Terminated
- Sponsor
- RAPT Therapeutics
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tivumecirnon in melanoma, sponsored by RAPT Therapeutics. Primary endpoints: Objective Response Rate at 1 year, Adverse Events at 3 weeks and 1 more. Started Sep 2021; status: terminated.
02
Drugs
tivumecirnon
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04894994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894994.